Enfusion, Inc. ENFN
We take great care to ensure that the data presented and summarized in this overview for Enfusion, Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding ENFN
View all-
Ftv Management Company, L.P. San Francisco, CA32.4MShares$318 Million100.0% of portfolio
-
Iconiq Capital, LLC San Francisco, CA14MShares$137 Million2.9% of portfolio
-
Brown Capital Management LLC Baltimore, MD7.21MShares$70.6 Million1.5% of portfolio
-
Hhlr Advisors, Ltd. Grand Cayman, E94.98MShares$48.7 Million1.08% of portfolio
-
Vanguard Group Inc Valley Forge, PA4.02MShares$39.3 Million0.0% of portfolio
-
Black Rock Inc. New York, NY3.08MShares$30.1 Million0.0% of portfolio
-
Ararat Capital Management, LP Westport, CT2.57MShares$25.2 Million8.42% of portfolio
-
Lead Edge Capital Management, LLC New York, NY2.41MShares$23.6 Million7.35% of portfolio
-
Nellore Capital Management LLC Palo Alto, CA2.08MShares$20.3 Million2.74% of portfolio
-
12 West Capital Management LP New York, NY1.9MShares$18.6 Million1.88% of portfolio
Latest Institutional Activity in ENFN
Top Purchases
Top Sells
About ENFN
Enfusion, Inc. provides software-as-a-service solutions for investment management industry in the United States, Europe, the Middle East, Africa, and the Asia Pacific. It provides portfolio management system, which generates a real-time investment book of record that consists of valuation and risk tools that allows users to analyze aggregated or decomposed portfolio data for chief investment officers (CIOs) and portfolio managers; and order and execution management system that enables portfolio managers, traders, compliance teams, and analysts to electronically communicate trade orders for a variety of asset classes, manage trade orders, and systemically enforce trading regulations and internal guidelines. The company also offers accounting/general ledger system, a real-time accounting book of record for chief financial officers, chief operating officers, accountants, and operations teams; Enfusion analytics system, which enables CIOs, portfolio managers, traders, and analysts to analyze portfolios through time horizons and automate customized visualized reports for internal and external stakeholders; and technology-powered and managed services. Enfusion Inc. was incorporated in 2021 and is headquartered in Chicago, Illinois.
Insider Transactions at ENFN
Insider Transaction List
View allDate | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
---|---|---|---|---|---|
Oct 22
2024
|
Matthew Campobasso General Counsel |
SELL
Open market or private sale
|
Direct |
674
-1.24%
|
$5,392
$8.95 P/Share
|
Sep 10
2024
|
Bronwen Bastone Chief People Officer |
SELL
Open market or private sale
|
Direct |
3,219
-1.62%
|
$25,752
$8.12 P/Share
|
Jun 20
2024
|
Bronwen Bastone Chief People Officer |
SELL
Open market or private sale
|
Direct |
18,241
-8.4%
|
$145,928
$8.11 P/Share
|
Jun 18
2024
|
Valeria Gutowski Chief Accounting Officer |
SELL
Open market or private sale
|
Direct |
1,258
-3.41%
|
$10,064
$8.17 P/Share
|
Jun 18
2024
|
Bronwen Bastone Chief People Officer |
SELL
Open market or private sale
|
Direct |
10,539
-4.63%
|
$84,312
$8.17 P/Share
|
Jun 18
2024
|
Matthew Campobasso General Counsel |
SELL
Open market or private sale
|
Direct |
1,651
-2.95%
|
$13,208
$8.17 P/Share
|
Jun 14
2024
|
Deirdre Somers Director |
SELL
Open market or private sale
|
Direct |
4,629
-9.66%
|
$37,032
$8.4 P/Share
|
Jun 13
2024
|
Kathleen De Rose Director |
BUY
Grant, award, or other acquisition
|
Direct |
13,470
+18.16%
|
-
|
Jun 13
2024
|
Jan Hauser Director |
BUY
Grant, award, or other acquisition
|
Direct |
13,470
+18.87%
|
-
|
Jun 13
2024
|
Michael Spellacy Director |
BUY
Grant, award, or other acquisition
|
Direct |
13,470
+19.17%
|
-
|
Jun 13
2024
|
Deirdre Somers Director |
BUY
Grant, award, or other acquisition
|
Direct |
13,470
+21.93%
|
-
|
Jun 13
2024
|
Lawrence E Leibowitz Director |
BUY
Grant, award, or other acquisition
|
Direct |
13,470
+7.13%
|
-
|
May 20
2024
|
Bronwen Bastone Chief People Officer |
SELL
Open market or private sale
|
Direct |
34,059
-13.01%
|
$306,531
$9.55 P/Share
|
Mar 05
2024
|
Oleg Movchan Chief Executive Officer |
BUY
Grant, award, or other acquisition
|
Direct |
249,701
+21.44%
|
-
|
Mar 01
2024
|
Neal Pawar Chief Operating Officer |
BUY
Grant, award, or other acquisition
|
Direct |
144,176
+10.85%
|
-
|
Mar 01
2024
|
Oleg Movchan Chief Executive Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
4,069
-1.43%
|
$32,552
$8.67 P/Share
|
Mar 01
2024
|
Oleg Movchan Chief Executive Officer |
BUY
Grant, award, or other acquisition
|
Direct |
13,887
+4.66%
|
$111,096
$8.67 P/Share
|
Mar 01
2024
|
Bronwen Bastone Chief People Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,906
-0.72%
|
$15,248
$8.67 P/Share
|
Mar 01
2024
|
Bronwen Bastone Chief People Officer |
BUY
Grant, award, or other acquisition
|
Direct |
109,812
+15.37%
|
$439,248
$4.34 P/Share
|
Mar 01
2024
|
Matthew Campobasso General Counsel |
SELL
Payment of exercise price or tax liability
|
Direct |
1,081
-1.9%
|
$8,648
$8.67 P/Share
|
Last 12 Months Summary
Grant, award, or other acquisition | 1.78M shares |
---|
Payment of exercise price or tax liability | 35.7K shares |
---|---|
Open market or private sale | 1.34M shares |